NovaSight Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$7.91M
- Investors
-
9
NovaSight General Information
Description
Developer of a pediatric ophthalmology medical device intended to integrate data analytics into a range of medical devices. The company aims to prevent vision impairments among pediatric patients using eye-tracking-based technology in novel diagnostic, therapeutic, and preventive solutions that are designed for the unique needs and attention span of children, enabling patients to receive the right eye care devices required.
Contact Information
Website
www.nova-sight.comCorporate Office
- 1 Hayarden Street
- Airport City
- Lod 7019900
- Israel
Corporate Office
- 1 Hayarden Street
- Airport City
- Lod 7019900
- Israel
NovaSight Timeline
NovaSight Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 03-Aug-2025 | $7.91M | Completed | Generating Revenue | ||
| 7. Later Stage VC (Series B) | 29-Dec-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 07-Dec-2022 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 01-May-2021 | Cancelled | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 13-Jul-2020 | Completed | Generating Revenue | |||
| 3. Grant | 01-Jan-2019 | Completed | Startup | |||
| 2. Angel (individual) | 01-Feb-2016 | $840K | $840K | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
NovaSight Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred B-3 Shares | ||||||||
| Preferred B-2 Shares | ||||||||
| Prefered A2 | ||||||||
| Preferred A1 | 33,000 | $0.010000 | $182.09 | $182.09 | 1x | $182.09 | 22.59% | |
| Preferred A | 34,000 | $0.010000 | $242.78 | $242.78 | 1x | $242.78 | 23.41% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NovaSight Comparisons
Industry
Financing
Details
NovaSight Competitors (3)
One of NovaSight’s 3 competitors is Luminopia, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Luminopia | Venture Capital-Backed | Cambridge, MA | ||||
| RightEye | Venture Capital-Backed | Bethesda, MD | ||||
| Vivid Vision | Venture Capital-Backed | San Francisco, CA |
NovaSight Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NovaSight Patents
NovaSight Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234486-A1 | Method and device for treating / preventing ophthalmological conditions | Pending | 08-May-2025 | ||
| WO-2023209540-A1 | Method and system for assessing axial length of the eye | Inactive | 25-Apr-2022 | ||
| EP-4456779-A1 | Method and device for treating / preventing refractive errors as well as for image processing and display | Pending | 27-Dec-2021 | ||
| EP-4456779-A4 | Method and device for treating / preventing refractive errors as well as for image processing and display | Pending | 27-Dec-2021 | ||
| US-11918287-B2 | Method and device for treating / preventing refractive errors as well as for image processing and display | Active | 27-Dec-2021 | A61B3/028 |
NovaSight Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NovaSight Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arbelon Holdings | Family Office | Minority | ||
| Sanara Capital | Venture Capital | Minority | ||
| Santen Pharmaceutical | Corporation | Minority | ||
| Yunjin (Suzhou) Capital Management | Growth/Expansion | Minority | ||
| Club 100 plus | Angel Group | Minority |
NovaSight FAQs
-
When was NovaSight founded?
NovaSight was founded in 2016.
-
Where is NovaSight headquartered?
NovaSight is headquartered in Lod, Israel.
-
What is the size of NovaSight?
NovaSight has 14 total employees.
-
What industry is NovaSight in?
NovaSight’s primary industry is Therapeutic Devices.
-
Is NovaSight a private or public company?
NovaSight is a Private company.
-
What is the current valuation of NovaSight?
The current valuation of NovaSight is .
-
What is NovaSight’s current revenue?
The current revenue for NovaSight is .
-
How much funding has NovaSight raised over time?
NovaSight has raised $38.2M.
-
Who are NovaSight’s investors?
Arbelon Holdings, Sanara Capital, Santen Pharmaceutical, Yunjin (Suzhou) Capital Management, and Club 100 plus are 5 of 9 investors who have invested in NovaSight.
-
Who are NovaSight’s competitors?
Luminopia, RightEye, and Vivid Vision are competitors of NovaSight.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
